PMID- 36142907
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230308
IS  - 2077-0383 (Print)
IS  - 2077-0383 (Electronic)
IS  - 2077-0383 (Linking)
VI  - 11
IP  - 18
DP  - 2022 Sep 6
TI  - Sodium-Glucose Cotransporter-2 Inhibitors Could Help Delay Renal Impairment in 
      Patients with Type 2 Diabetes: A Real-World Clinical Setting.
LID - 10.3390/jcm11185259 [doi]
LID - 5259
AB  - This study compared the renoprotective effects of sodium-glucose cotransporter-2 
      (SGLT2) inhibitors and dipeptidyl peptidase-4 (DPP-4) inhibitors in patients with 
      type 2 diabetes mellitus (T2DM). We performed a retrospective cohort study using 
      electronic medical records of patients with T2DM. The primary outcome was the 
      first occurrence of an estimated glomerular filtration rate (eGFR) <45 
      mL/min/1.73 m2 after the index date. We analyzed changes in repeatedly measured 
      laboratory data, such as eGFR and serum uric acid (SUA). We included 2396 
      patients (1198 patients in each group) in the present study. The rate of renal 
      events was significantly lower in the SGLT2 inhibitors group than that in the 
      DPP-4 inhibitors group (hazard ratio, 0.46; 95% CI, 0.29 to 0.72; p = 0.0007). 
      The annual mean change in the eGFR was significantly smaller in the SGLT2 
      inhibitors group than that in the DPP-4 inhibitors group, with a between-group 
      difference of 0.86 +/- 0.18 mL/min/1.73 m2 per year (95% CI, 0.49 to 1.23; p < 
      0.0001). Moreover, the mean change in SUA was lower in the SGLT2 inhibitors 
      group. Considering the lower incidence of renal impairment, the slower decline in 
      eGFR, and reduced SUA, SGLT2 inhibitors could help delay renal impairment in 
      patients with T2DM.
FAU - Park, Gyunam
AU  - Park G
AD  - Department of Pharmacy and Yonsei Institute of Pharmaceutical Sciences, Yonsei 
      University, Incheon 21983, Korea.
FAU - Choi, Byungha
AU  - Choi B
AD  - Department of Pharmacy and Yonsei Institute of Pharmaceutical Sciences, Yonsei 
      University, Incheon 21983, Korea.
AD  - Graduate Program of Industrial Pharmaceutical Science, Yonsei University, Incheon 
      21983, Korea.
FAU - Kang, Soyoung
AU  - Kang S
AD  - Department of Pharmacy and Yonsei Institute of Pharmaceutical Sciences, Yonsei 
      University, Incheon 21983, Korea.
AD  - Department of Pharmaceutical Medicine and Regulatory Science, Yonsei University, 
      Incheon 21983, Korea.
FAU - Kim, Bomin
AU  - Kim B
AD  - Department of Pharmacy and Yonsei Institute of Pharmaceutical Sciences, Yonsei 
      University, Incheon 21983, Korea.
FAU - Chang, Min Jung
AU  - Chang MJ
AUID- ORCID: 0000-0002-8408-5907
AD  - Department of Pharmacy and Yonsei Institute of Pharmaceutical Sciences, Yonsei 
      University, Incheon 21983, Korea.
AD  - Graduate Program of Industrial Pharmaceutical Science, Yonsei University, Incheon 
      21983, Korea.
AD  - Department of Pharmaceutical Medicine and Regulatory Science, Yonsei University, 
      Incheon 21983, Korea.
LA  - eng
PT  - Journal Article
DEP - 20220906
PL  - Switzerland
TA  - J Clin Med
JT  - Journal of clinical medicine
JID - 101606588
PMC - PMC9502124
OTO - NOTNLM
OT  - antidiabetic drug
OT  - diabetic kidney disease (DKD)
OT  - renoprotective effect
OT  - sodium-glucose cotransporter-2 (SGLT2) inhibitor
COIS- We report no potential conflict of interest in this study.
EDAT- 2022/09/24 06:00
MHDA- 2022/09/24 06:01
PMCR- 2022/09/06
CRDT- 2022/09/23 01:27
PHST- 2022/07/29 00:00 [received]
PHST- 2022/08/28 00:00 [revised]
PHST- 2022/09/03 00:00 [accepted]
PHST- 2022/09/23 01:27 [entrez]
PHST- 2022/09/24 06:00 [pubmed]
PHST- 2022/09/24 06:01 [medline]
PHST- 2022/09/06 00:00 [pmc-release]
AID - jcm11185259 [pii]
AID - jcm-11-05259 [pii]
AID - 10.3390/jcm11185259 [doi]
PST - epublish
SO  - J Clin Med. 2022 Sep 6;11(18):5259. doi: 10.3390/jcm11185259.